Osteosarcoma

P=N/A, N=40, Active, not recruiting, Sakarya University

Drug sensitivity analysis revealed differential responses to 4 drugs between the risk groups, with the 3 ORGs (ACSS2, CLTCL1 and PLD3) showing positive correlations with 2 drugs (BI_2536, Dactinomycin). Additionally, functional experiments confirmed the role of ACSS2 in OS cell behavior. This novel ORG signature not only provides a valuable tool for patient stratification but also offers insights into the biological processes driving OS progression and potential therapeutic targets.

In contrast, the distribution pattern of SET oncoprotein immunolabelling was relatively consistent across tumour types, with no statistically significant differences observed. Melanoma, mammary carcinoma, squamous cell carcinoma, prostatic carcinoma, osteosarcoma and transmissible venereal tumour showed the highest immunolabelling intensity patterns, highlighting the importance of SET oncoprotein as a potential therapeutic target and paving the way for future studies on its use in personalized therapy.

P2/3, N=140, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Dec 2026 --> Mar 2026

Stromal p63 and CD10 were commonly expressed in GCTB. CD10-high expression was associated with recurrent-case status in univariate analysis, but this exploratory finding should not be interpreted as recurrence prediction.

In vitro experiments confirmed the tumor-suppressive role of CIB1 inhibition. These findings highlight CIB1 as a promising therapeutic target for osteosarcoma treatment.

Overall, our findings position ZEB1 as a critical driver of OS aggressiveness by regulating stemness, cellular differentiation, oncogenic signaling, and immune infiltration, and highlight differentiation-based therapeutic strategies as a promising avenue for osteosarcoma treatment.

Key findings were validated by CETSA, isothermal dose-response fingerprinting, co-immunoprecipitation, and ubiquitination assays. These results demonstrate that shogaol exerts dual cytotoxic effects through the PLK1/NPM1 axis, presenting a potential natural therapeutic approach for Ewing sarcoma.

P1, N=16, Recruiting, Sun Yat-sen University

These findings suggest that lenvatinib suppresses osteosarcoma cell proliferation, migration, and invasion, at least in part, by inducing ferroptosis-related changes associated with modulation of the p-STAT3/p53/xCT axis. This study reveals a previously underrecognized mechanism of lenvatinib action and supports further investigation of ferroptosis-targeted strategies in osteosarcoma.

Our studies revealed DBD-α4 helix is crucial for cooperative binding of EWSR1::FLI1 at GGAA microsatellites. This binding underlies many aspects of genome regulation by EWSR1::FLI1, such as formation of topologically associated domains (TADs), chromatin loops, enhancers, and productive transcription hubs.